The role of SARS-CoV-2 immunosuppression and the therapy used to manage COVID-19 disease in the emergence of opportunistic fungal infections: A review
Open Access
- 3 August 2022
- journal article
- review article
- Published by Elsevier BV in Current Research in Biotechnology
- Vol. 4, 337-349
- https://doi.org/10.1016/j.crbiot.2022.08.001
Abstract
No abstract availableKeywords
This publication has 121 references indexed in Scilit:
- Risk Factors for Cryptococcal Meningitis: A Single United States Center ExperienceMycopathologia, 2016
- Breaking the MoldAnnals of Pharmacotherapy, 2016
- CryptococcosisInfectious Disease Clinics of North America, 2016
- Influenza virus-induced lung injury: pathogenesis and implications for treatmentEuropean Respiratory Journal, 2015
- The emerging world of the fungal microbiomeTrends in Microbiology, 2013
- Predictors of Mortality and Differences in Clinical Features among Patients with Cryptococcosis According to Immune StatusPLOS ONE, 2013
- Clinical Practice Guidelines for the Management of Patients with Histoplasmosis: 2007 Update by the Infectious Diseases Society of AmericaClinical Infectious Diseases, 2007
- Mucormycosis and entomophthoramycosis: a review of the clinical manifestations, diagnosis and treatmentClinical Microbiology & Infection, 2004
- Voriconazole versus Amphotericin B for Primary Therapy of Invasive AspergillosisThe New England Journal of Medicine, 2002
- Immunodeficiency of the ElderlyClinical Infectious Diseases, 1987